Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial
    Meeting Abstract

    Bardia, A.; Jhaveri, K.; Im, S. A.; Pernas Simon, S.; De Laurentiis, M.; Wang, S.; Martinez, N.; Santos Borges, G.; Cescon, D. W.; Hattori, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Novel therapeutic opportunities in metaplastic breast cancer
    Meeting Abstract

    Pareja, F.; Gazzo, A.; Dopeso, H.; Brown, D.; Selenica, P.; Zhu, Y.; Blanco Heredia, J.; Gusain, L.; Pei, X.; Marra, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • APOBEC mutagenesis and macrophage infiltration in cancer
    Meeting Abstract

    Gazzo, A.; Marra, A.; Zhu, Y.; Gupta, A.; Selenica, P.; Pei, X.; Weigelt, B.; Pareja, F.; Riaz, N.; Reis, J. S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Pan-cancer assessment of the impact of intronic variants on cancer development and progression
    Meeting Abstract

    Safonov, A.; Mehine, M.; Ceyhan-Birsoy, O.; Brown, D.; Bandlamudi, C.; Forbes, A.; Gazzo, A.; Selenica, P.; Shen, R.; Khurana, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Remote symptom monitoring with electronic patient-reported outcomes (ePROs) during treatment for metastatic cancer: Results from the PRO-TECT trial (Alliance AFT-39)
    Meeting Abstract

    Basch, E.; Schrag, D.; Jansen, J.; Ginos, B.; Spears, P. A.; Jonsson, M.; Carr, P.; Deal, A. M.; Thanarajasingam, G.; Reeve, B. B.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Imlunestrant with or without everolimus or alpelisib, in ER+, HER2-advanced breast cancer (aBC): Results from the phase Ia/b EMBER
    Meeting Abstract

    Jhaveri, K.; Jeselsohn, R.; Ma, C. X.; Lim, E.; Yonemori, K.; Hamilton, E. P.; Harnden, K.; Im, S. A.; Beck, T.; Sammons, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC)
    Meeting Abstract

    Tsurutani, J.; Jacot, W.; Yamashita, T.; Riaz, F.; Yerushalmi, R.; Im, S. A.; Niikura, N.; Halser-Strub, U.; CorteĢs, J.; Wennstig, A. K.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Aspire to ASCENT: Real-world outcomes from patients with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (Saci) in a single academic institution
    Meeting Abstract

    Walsh, E. M.; Klar, M.; Abuhadra, N.; Robson, M.; Drago, J.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: An exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC)
    Meeting Abstract

    Goetz, M. P.; Turner, N.; Sasano, H.; Arteaga, C.; Chandarlapaty, S.; Loi, S.; Reis-Filho, J. S.; Kreipe, H.; Harbeck, N.; Fasching, P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic implications of HER2 gain in patients with HR+/ HER2-breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC)
    Meeting Abstract

    Ferraro, E.; Chew Minmin, S.; Nemirovsky, D.; Chen, Y.; Barrio, A. V.; Modi, S.; Seidman, A.; Wen, H.; Brogi, E.; Robson, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save